Hypersensitivity News and Research

RSS

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.

CSL, PharmaJet partner for needle-free delivery of Afluria influenza vaccine

PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria influenza vaccine to be delivered with the PharmaJet Stratis needle-free jet injector, as soon as the 2013-2014 flu season.

30 Nov 2012

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

EC approves Regeneron’s EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).

27 Nov 2012

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

Patients with obsessive-compulsive disorder worry considerably more than general population

Patients with obsessive-compulsive disorder are characterised by persistent thoughts and repetitive behaviours. A new study reveals that sufferers worry considerably more than the general population in the face of morality problems.

9 Nov 2012

Pradaxa use does not appear to increase serious bleeding

The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.

4 Nov 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Navigating the Labyrinth of Traumatic Brain Injury to Discover a Secondary Neurological Condition

Working with individuals with traumatic brain injury (TBI) every day, I see the debilitating effects and long-term struggles firsthand.

9 Oct 2012

New JEBDP series provides updates on evidence-based care in periodontics and implant dentistry

What's the latest, research-supported best practice in periodontal care and implant dentistry? Dental specialists and generalists alike can read about it in the first of a new series from The Journal of Evidence-Based Dental Practice (JEBDP), the foremost publication of information about evidence-based dental practice, published by Elsevier.

4 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

No link between low-level electromagnetic field exposure from mobile phones and health risks

There is no scientific evidence that low-level electromagnetic field exposure from mobile phones and other transmitting devices causes adverse health effects, according to a report presented by a Norwegian Expert Committee. In addition, the Committee provides advice to authorities about risk management and regulatory practice.

18 Sep 2012

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Pfizer Oncology today announced that important data from its lung cancer and renal cell carcinoma (RCC) portfolios will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Vienna, Austria, September 28 - October 2, 2012.

18 Sep 2012

Interventions can help prevent older people from falling

There is now strong evidence that some interventions can prevent falls in people over the age of 65 who are living in their own homes. However, the researchers who reached this conclusion say that care is needed when choosing interventions, as some have no effect. The full details are published this month in The Cochrane Library. This is an update of a previous report that contains data from 51 additional trials, enabling the authors to reach many more conclusions.

12 Sep 2012

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Hypersensitivity News and Research

CSL, PharmaJet partner for needle-free delivery of Afluria influenza vaccine

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

EC approves Regeneron’s EYLEA for treatment of wet AMD

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Patients with obsessive-compulsive disorder worry considerably more than general population

Pradaxa use does not appear to increase serious bleeding

FDA accepts Sunovion’s two LATUDA sNDAs for review

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Navigating the Labyrinth of Traumatic Brain Injury to Discover a Secondary Neurological Condition

New JEBDP series provides updates on evidence-based care in periodontics and implant dentistry

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

No link between low-level electromagnetic field exposure from mobile phones and health risks

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Interventions can help prevent older people from falling

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News